Chemotherapy combination regimens for EGFR-TKI resistant metastatic EGFR-mutated NSCLC: A systematic review and network meta-analysis

被引：0
|
作者：
Qin, B. [1 ]
Jiao, X. [1 ]
Liu, K. [1 ]
Zang, Y. [1 ]
机构：
[1] Shanghai Changzheng Hosp, Dept Med Oncol, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.697
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
664P
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Meta-analysis of the chemotherapy versus EGFR-TKI in different selections of patients.
    Xu, C.
    Zhou, Q.
    Wu, Y. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [42] A phase II trial of atezolizumab, bevacizumab, pemetrexed and carboplatin combination for metastatic EGFR-mutated NSCLC after TKI failure
    Lam, T. C.
    Tsang, K.
    Choi, H.
    Lee, V. H. F.
    Lam, K. O.
    Chiang, C. L.
    So, T. H.
    Chan, W. W.
    Nyaw, S. F.
    Lim, F.
    Lau, J. O.
    Chik, J.
    Kong, S. F.
    Lee, A. W. M.
    ANNALS OF ONCOLOGY, 2020, 31 : S1389 - S1389
  • [43] EGFR-TKI Plus Anti-Angiogenic Drugs in EGFR-Mutated Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials
    Conforti, Fabio
    Pala, Laura
    Bagnardi, Vincenzo
    Specchia, Claudia
    Oriecuia, Chiara
    Marra, Antonio
    Zagami, Paola
    Morganti, Stefania
    Tarantino, Paolo
    Catania, Chiara
    De Marinis, Filippo
    Queirolo, Paola
    De Pas, Tommaso
    JNCI CANCER SPECTRUM, 2020, 4 (06)
  • [44] Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis
    Lee, H. J.
    Jeong, G. H.
    Li, H.
    Kim, M. S.
    Kim, J. S.
    Park, S. J.
    Han, Y. J.
    Lee, K. H.
    Kronbichler, A.
    Hong, S. H.
    Ghayda, R. A.
    Luchini, C.
    Nottegar, A.
    Koyanagi, A.
    Smith, L.
    Jacob, L.
    Dragioti, E.
    Radua, J.
    Cargnin, S.
    Terrazzino, S.
    Thompson, T.
    Yon, D. K.
    Lee, S. W.
    Yang, J. M.
    Wasuwanich, P.
    Shin, J. I.
    Gamerith, G.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (20) : 6232 - 6244
  • [45] Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy
    Qin, Bao-Dong
    Jiao, Xiao-Dong
    Yuan, Ling-Yan
    Wu, Ying
    Ling, Yan
    Zang, Yuan-Sheng
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (04)
  • [46] Comparative Efficacy and Safety of TKIs Alone or in Combination With Antiangiogenic Agents in Advanced EGFR-Mutated NSCLC as the First-Line Treatment: A Systematic Review and Meta-Analysis
    Zhang, Shuang
    Li, Shuang
    Liu, Jingjing
    Yang, Changliang
    Zhang, Liang
    Bao, Hao
    Cheng, Ying
    CLINICAL LUNG CANCER, 2022, 23 (02) : 159 - 169
  • [47] Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure
    Lam, T. C.
    Tsang, K. C.
    Choi, H. C.
    Lee, V. H.
    Lam, K. O.
    Chiang, C. L.
    So, T. H.
    Chan, W. W.
    Nyaw, S. F.
    Lim, F.
    Lau, J. O.
    Chik, J.
    Kong, F. M.
    Lee, A. W.
    LUNG CANCER, 2021, 159 : 18 - 26
  • [48] Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials
    Sun, Li
    Guo, Yi-Jia
    Song, Jun
    Wang, Yan-Ru
    Zhang, Shu-Ling
    Huang, Le-Tian
    Zhao, Jian-Zhu
    Jing, Wei
    Han, Cheng-Bo
    Ma, Jie-Tao
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [49] Pooled safety analysis of EGFR-TKI therapy in patients with EGFR-mutated non-small cell lung cancer.
    Takada, Masayuki
    Okamoto, Isamu
    Nakagawa, Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] A Phase Ib Study of the Combination of Afatinib and Ruxolitinib in EGFR Mutant NSCLC Progressed on EGFR-TKI: An Updated Analysis
    Park, J. S.
    Hong, M. H.
    Cho, B. C.
    Kim, H. R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1847 - S1847
12345